Bisphosphonates (BPs)

  • Reiner Bartl
  • Christoph Bartl


A new era in the treatment of disorders of bone began about 45 years ago with the introduction of BP into clinical practice. BPs are deposited on the surface of the bones and inhibit osteoclasts and thus resorption of bone. Consequently these drugs have long been given to patients with Morbus Paget, with hypercalcaemia, with multiple myeloma and with osseous metastases. BPs not only inhibit resorption of bone, but they also inhibit growth of metastases in bone and marrow.


Bone mineral density Fracture risk Bone density Bisphosphonate therapy Mevalonic acid 

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Reiner Bartl
    • 1
  • Christoph Bartl
    • 1
    • 2
  1. 1.Osteoporosis and Bone CenterMunichGermany
  2. 2.Center of Orthopaedics and Sports MedicineMunichGermany

Personalised recommendations